For decades, pancreatic cancer has been the kind of diagnosis doctors dread giving and patients fear hearing. Now, a Spanish research team reports results in animals that hint at a different future, based on a triple attack against the tumour’s core machinery.
Why pancreatic cancer is so feared
Pancreatic cancer kills fast and quietly. Symptoms often appear late, such as vague abdominal pain, weight loss, or jaundice, when the disease has already spread.
In Spain alone, more than 10,000 people are diagnosed every year. Fewer than one in ten are still alive five years later. The figures are similar across much of Europe and the US.
The problem comes from several directions. The pancreas sits deep in the abdomen, so tumours remain hidden on routine checks. The cancer itself grows aggressively. Standard chemotherapy has limited impact. Even cutting‑edge targeted drugs bring only short‑lived relief.
At the heart of many of these tumours lies a mutated gene called KRAS. Around 90% of pancreatic cancers carry some form of KRAS alteration, which acts like a stuck accelerator pedal, telling cells to grow and divide without restraint.
Pharmaceutical companies have spent years chasing KRAS. Some new drugs can switch it off for a while. Yet the cancer usually finds a way around the blockade. Alternate signalling routes switch on, or new mutations emerge, and the tumour begins to progress again.
Pancreatic tumours behave like expert escape artists, slipping free from one drug after another by rewiring their growth signals.
This constant pattern of brief success followed by relapse pushed researchers in Madrid to rethink the whole playbook.
A triple therapy that shuts down tumour growth in mice
The new work comes from the Spanish National Cancer Research Centre (CNIO) in Madrid, led by veteran cancer biologist Mariano Barbacid. His group has spent years building realistic mouse models of pancreatic cancer that closely mimic the human disease.
➡️ Your morning routine might be sabotaging your brain without you realising it
➡️ Bad news : Starting March 15, a prohibits mowing lawns between noon and 4 p.m.
➡️ Bird lovers use this cheap December treat to keep feeders busy and attract birds every morning
Instead of betting on a single weapon, the team combined three different drugs aimed at separate, but connected, nodes in the KRAS signalling web.
The three‑pronged attack
- Daraxonrasib: an experimental inhibitor designed to directly target mutant KRAS.
- Afatinib: a drug already approved for some lung cancers that blocks growth signals from receptors at the cell surface.
- SD36: a compound that tags specific proteins for destruction, further crippling the tumour’s internal communication lines.
The idea is simple in concept and ambitious in practice: if the cancer can dodge one blow, make sure it faces three at once.
Instead of clipping a single wire, the Spanish team cut through several cables at the same time, leaving the tumour’s control panel dark.
In three independent mouse models of pancreatic cancer, the triple therapy produced what researchers rarely see in this disease: complete regression of established tumours. Imaging and tissue analysis showed that the cancers shrank away and then disappeared.
Equally striking, the CNIO team reported no serious toxicity in the animals. The mice tolerated the drugs, maintained weight, and did not show obvious organ damage during the study period.
When treatment stopped, the tumours did not immediately grow back. For a cancer known for rapid recurrence, that detail stands out. It suggests the triple combination left the malignant cells with little room to evolve an escape route.
Why hitting multiple targets changes the game
Oncologists often compare tumour biology to a network of roads. Block one motorway, and traffic diverts through smaller side streets. Targeted drugs that focus on a single protein can be powerful at first, but cancer cells usually reroute their signalling.
The Spanish strategy tries to close several exits at once. By acting at different levels of the KRAS‑controlled cascade, the three molecules disrupt upstream signals at the cell surface, the mutant gene itself, and some of the downstream effectors.
Researchers liken it to suspending a bridge with three cables instead of one. Cut one cable and the bridge wobbles but holds. Cut all three and it collapses. The tumour, faced with simultaneous pressure on several survival routes, has fewer options to adapt.
This approach contrasts sharply with earlier attempts that layered more chemotherapy onto already fragile patients. Here, the sophistication lies not in using harsher drugs, but in choosing targets that work together mechanistically.
From mouse success to human trials: a long road ahead
Despite the excitement, the CNIO team is urging caution. Results in mice, even in advanced models, often fail to translate directly into people.
Human bodies process drugs differently. Doses that seem safe in animals can produce side effects in patients, especially when combinations are involved. Long‑term toxicity remains completely unknown for this specific trio.
Before any patient receives the full triple regimen, researchers will need to:
- fine‑tune dosing schedules to balance efficacy and safety
- study drug–drug interactions in more depth
- run further toxicology tests in larger animals
- design early‑phase clinical trials that escalate risk gradually
The leap from curing cancer in mice to helping people is big, slow and full of obstacles, but not impossible.
Barbacid has stressed that clinical testing is not imminent. Several years of lab work and regulatory review are likely before a first volunteer with pancreatic cancer receives some version of this combination.
Implications for other stubborn cancers
Even at this stage, the concept resonates far beyond pancreatic disease. Many hard‑to‑treat tumours, such as certain lung and colorectal cancers, also rely on KRAS or similar signalling networks.
If multi‑target approaches prove workable, oncologists might adapt the blueprint to other settings: combining a KRAS inhibitor with drugs aimed at companion pathways, or pairing targeted agents with immune therapies.
Funding bodies are paying attention. The project has drawn support from organisations including CRIS Cancer Foundation and the European Research Council, signalling faith in strategies that challenge old assumptions.
What patients and families can realistically expect
For someone facing pancreatic cancer today, this news does not change current treatment options. Surgery, when possible, remains the best chance of extended survival. Chemotherapy regimens such as FOLFIRINOX or gemcitabine‑based combinations still anchor standard care.
Where this breakthrough matters is in the horizon it draws. It shows that even a notoriously resistant tumour can be pushed into full regression in animals when scientists abandon the one‑target mindset.
Oncologists may soon talk to newly diagnosed patients about ongoing trials that aim to shut several tumour circuits at once. That kind of conversation can shape decisions about second‑line treatments or participation in research studies.
Key terms that often confuse people
| Term | What it means in plain language |
|---|---|
| KRAS | A gene that helps control how cells grow. When mutated, it can keep cells in permanent “grow” mode. |
| Targeted therapy | Drugs designed to hit specific molecules in cancer cells, instead of broadly attacking all fast‑growing cells. |
| Resistance | When a tumour stops responding to a treatment that used to work, often by finding a new way to grow. |
| Regression | A measurable shrinkage of the tumour. Complete regression means doctors can no longer detect it. |
What this kind of research could mean for future care
Imagine a patient diagnosed in ten years’ time with a KRAS‑mutant pancreatic tumour. Instead of moving straight to broad chemotherapy, their doctor might first send a biopsy for deep molecular profiling. The report would guide a personalised combination: one drug for KRAS, one for a key receptor, and one that degrades a critical downstream protein.
The risks will still be real. Combining multiple potent agents can increase chances of side effects such as skin reactions, diarrhoea, liver stress or blood‑cell problems. Some patients may tolerate only parts of the regimen. Others might see their cancer evolve resistance despite the triple hit.
Yet even partial improvements matter in this disease. Extending survival by months while preserving quality of life can give people time for additional lines of therapy, experimental trials, or simply more days at home with family.
As research continues, the central idea from Madrid stays clear: the way to challenge one of the deadliest cancers may lie not in one miracle pill, but in coordinated strikes on several weak points at once.